^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    GDA-501

    i
    Other names: GDA-501, CAR-HER2 NK cell therapy
    Company:
    Ayrmid
    Drug class:
    NK cell stimulant
    Related drugs:
    2years
    GDA-501: Engineered NAM-NK cells with HER2-CAR expression demonstrate increased cytotoxicity against HER2-expressing solid tumors (SITC 2022)
    Methods HER2-CAR-NK cells were developed based on a single-chain variable fragment (scFv) of the widely used humanized monoclonal antibody trastuzumab. Informed consent has been approved by the ECs. The Israeli template of informed consent is in used and it includes study specific information (e.g. study goal, design, method, duration, risks, etc.).
    IO biomarker
    |
    HER-2 (Human epidermal growth factor receptor 2) • TNFA (Tumor Necrosis Factor-Alpha) • LAMP1 (Lysosomal Associated Membrane Protein 1)
    |
    HER-2 expression • HER-2 elevation
    |
    Herceptin (trastuzumab) • GDA-501 • GDA-201